BVS - Company ID 0001665988
The table below shows Bioventus Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $568.09M | $573.28M | $512.35M | $512.12M | $430.90M | $321.16M |
| Cost of revenue | $179.93M | $185.05M | $184.15M | $181.04M | $128.19M | $87.64M |
| Gross profit | $388.16M | $388.23M | $328.19M | $331.08M | $302.71M | $233.52M |
| R&D | $12.11M | $13.95M | $13.45M | $23.85M | $19.04M | $11.20M |
Bioventus Inc. reported annual revenue of $568.09M for fiscal year 2025. That is down 0.9% from $573.28M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $340.14M (FY 2019) to $568.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $314.03M |
| $343.80M |
| $303.88M |
| $332.13M |
| $254.25M |
| $193.08M |
| Operating income | $53.98M | -$15.20M | -$81.72M | -$167.23M | $12.06M | $21.24M |
| Income tax | -$1.56M | -$5.29M | $85.00K | -$44.37M | -$1.97M | $1.19M |
| Net income | $22.73M | -$36.13M | -$156.23M | -$158.70M | $19.38M | $16.41M |
| EPS (diluted) | $0.33 | -$0.56 | -$2.49 | -$2.59 | -$0.15 | - |